An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.